Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma, Inc. ( LYEL ) is a CAR-T therapy developer. The story is centered around a single asset known as ronde-cel. Target indication is LBCL, where it demonstrated 93% ORR, 76% CR, and ~18-month mPFS inMr Arunangshu Das is a software engineer, a finance and billing architect, and an active investor and entrepreneur. He is developing Tranzoro Investments to fill a critical lacunae - to help US investors understand Indian markets, and Indian investor understand US markets. For the former, he will ...